Figure 5.
Subsequent therapy just after investigational agent discontinuation. †Four of 13 patients continued administration of nivolumab as a commercially available drug after acquisition of marketing approval.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.